Flow Cytometry Technique Assessed for Signaling Pathways
|
By LabMedica International staff writers Posted on 24 Apr 2018 |

Image: The Navios clinical flow cytometer (Photo courtesy of Beckman Coulter).
Platelet aggregation is a key parameter in arterial thrombosis, leading to myocardial infarction or ischemic stroke. Platelets have several receptors sensitive to different stimuli and drugs that modulate aggregation with potential critical clinico-pathological significance.
Platelet intracellular signaling is essential for platelet function but difficult to study because of the small size and the need for delicate manipulation of platelets and because the reference techniques require large cell volumes and sample preparation. Flow cytometry is often used in routine clinical laboratories.
A team of scientists collaborating with CHU Saint-Etienne, Hôpital Nord (Saint-Etienne, France) assessed degree of platelet vasodilator-stimulated phosphoprotein (VASP) phosphorylation on patients hospitalized for a non-cardio-embolic ischemic stroke, included in an observational study. The patients, 12 men, seven women with a mean age of 72 years, were enrolled in the study between November 2014 and September 2015, and were treated orally with a regular daily dose of 75 mg of clopidogrel for at least five days to be at steady state, before blood was drawn.
The VASP assay was performed using the PLT VASP/P2Y12 kit. In addition, the Platelet PerFix flow cytometry method was developed from the PerFix EXPOSE kit provided for leukocytes. The team adapted the manufacturer's instruction for this kit. The fixation, permeabilization, staining and washing reagents of the kit were used. Each step was performed at room temperature. Platelets were analyzed on a Navios cytometer using Navios software (Beckman-Coulter) within one hour after the preparation was completed. Maximum platelet aggregation induced by adenosine diphosphate (ADP) was measured by Light Transmittance Aggregometry or LTA.
The investigators found poor agreement between prevention by adenosine diphosphate (ADP) of PGE1-induced cAMP-mediated VASP phosphorylation and ADP induced aggregation assessed by Light Transmittance Aggregometry. They did find a significant correlation between the PLT VASP/P2Y12 kit and the PerFix EXPOSE kit. The PerFix EXPOSE kit may also be helpful to monitor adverse effects of second-generation tyrosine kinase inhibitors on platelets as this new method can detect low responders to clopidogrel. The study was published originally on-line on February 16, 2018, in the journal Practical Laboratory Medicine.
Related Links:
CHU Saint-Etienne
Platelet intracellular signaling is essential for platelet function but difficult to study because of the small size and the need for delicate manipulation of platelets and because the reference techniques require large cell volumes and sample preparation. Flow cytometry is often used in routine clinical laboratories.
A team of scientists collaborating with CHU Saint-Etienne, Hôpital Nord (Saint-Etienne, France) assessed degree of platelet vasodilator-stimulated phosphoprotein (VASP) phosphorylation on patients hospitalized for a non-cardio-embolic ischemic stroke, included in an observational study. The patients, 12 men, seven women with a mean age of 72 years, were enrolled in the study between November 2014 and September 2015, and were treated orally with a regular daily dose of 75 mg of clopidogrel for at least five days to be at steady state, before blood was drawn.
The VASP assay was performed using the PLT VASP/P2Y12 kit. In addition, the Platelet PerFix flow cytometry method was developed from the PerFix EXPOSE kit provided for leukocytes. The team adapted the manufacturer's instruction for this kit. The fixation, permeabilization, staining and washing reagents of the kit were used. Each step was performed at room temperature. Platelets were analyzed on a Navios cytometer using Navios software (Beckman-Coulter) within one hour after the preparation was completed. Maximum platelet aggregation induced by adenosine diphosphate (ADP) was measured by Light Transmittance Aggregometry or LTA.
The investigators found poor agreement between prevention by adenosine diphosphate (ADP) of PGE1-induced cAMP-mediated VASP phosphorylation and ADP induced aggregation assessed by Light Transmittance Aggregometry. They did find a significant correlation between the PLT VASP/P2Y12 kit and the PerFix EXPOSE kit. The PerFix EXPOSE kit may also be helpful to monitor adverse effects of second-generation tyrosine kinase inhibitors on platelets as this new method can detect low responders to clopidogrel. The study was published originally on-line on February 16, 2018, in the journal Practical Laboratory Medicine.
Related Links:
CHU Saint-Etienne
Latest Hematology News
- Automated Hemostasis System Helps Labs of All Sizes Optimize Workflow
- Fast and Easy Test Could Revolutionize Blood Transfusions
- High-Sensitivity Blood Test Improves Assessment of Clotting Risk in Heart Disease Patients
- AI Algorithm Effectively Distinguishes Alpha Thalassemia Subtypes
- MRD Tests Could Predict Survival in Leukemia Patients
- Platelet Activity Blood Test in Middle Age Could Identify Early Alzheimer’s Risk
- Microvesicles Measurement Could Detect Vascular Injury in Sickle Cell Disease Patients
- ADLM’s New Coagulation Testing Guidance to Improve Care for Patients on Blood Thinners
- Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage
- Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments
- Platelets Could Improve Early and Minimally Invasive Detection of Cancer
- Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment
- Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
- First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes

- New Scoring System Predicts Risk of Developing Cancer from Common Blood Disorder
- Non-Invasive Prenatal Test for Fetal RhD Status Demonstrates 100% Accuracy
Channels
Clinical Chemistry
view channel
New PSA-Based Prognostic Model Improves Prostate Cancer Risk Assessment
Prostate cancer is the second-leading cause of cancer death among American men, and about one in eight will be diagnosed in their lifetime. Screening relies on blood levels of prostate-specific antigen... Read more
Extracellular Vesicles Linked to Heart Failure Risk in CKD Patients
Chronic kidney disease (CKD) affects more than 1 in 7 Americans and is strongly associated with cardiovascular complications, which account for more than half of deaths among people with CKD.... Read moreMolecular Diagnostics
view channel
Liquid Biopsy Could Replace Surgical Biopsy for Diagnosing Primary Central Nervous Lymphoma
Primary central nervous system lymphoma (PCNSL) is typically diagnosed through surgical biopsy, which remains the gold standard but carries substantial risk. Operability depends heavily on tumor location,... Read more
New Tool Reveals Hidden Metabolic Weakness in Blood Cancers
Acute myeloid leukemia (AML) is one of the most aggressive blood cancers, marked by poor survival rates and limited treatment options, especially in patients who do not respond to standard therapies.... Read moreImmunology
view channelBlood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug
Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more
Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment
Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more
Ultrasensitive Liquid Biopsy Demonstrates Efficacy in Predicting Immunotherapy Response
Immunotherapy has transformed cancer treatment, but only a small proportion of patients experience lasting benefit, with response rates often remaining between 10% and 20%. Clinicians currently lack reliable... Read moreMicrobiology
view channelAI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Infections caused by the pathogenic yeast Candida auris pose a significant threat to hospitalized patients, particularly those with weakened immune systems or those who have invasive medical devices.... Read more
New Test Measures How Effectively Antibiotics Kill Bacteria
Antibiotics are typically evaluated by how well they inhibit bacterial growth in laboratory tests, but growth inhibition does not always mean the bacteria are actually killed. Some pathogens can survive... Read morePathology
view channel
AI Algorithms Improve Genetic Mutation Detection in Cancer Diagnostics
Accurately identifying genetic mutations is central to cancer diagnostics and genomic research, but current methods struggle with complex sequencing data and limited clinical samples. Tumor analysis often... Read more
Skin Biopsy Offers New Diagnostic Method for Neurodegenerative Diseases
Transthyretin amyloidosis (ATTR) is a rare, progressive, and highly aggressive disease caused by the misfolding of a specific protein that accumulates as toxic amyloid filaments in multiple organs.... Read moreTechnology
view channelAptamer Biosensor Technology to Transform Virus Detection
Rapid and reliable virus detection is essential for controlling outbreaks, from seasonal influenza to global pandemics such as COVID-19. Conventional diagnostic methods, including cell culture, antigen... Read more
AI Models Could Predict Pre-Eclampsia and Anemia Earlier Using Routine Blood Tests
Pre-eclampsia and anemia are major contributors to maternal and child mortality worldwide, together accounting for more than half a million deaths each year and leaving millions with long-term health complications.... Read moreIndustry
view channel
Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform
Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more







